10x Genomics, Inc.
10x Genomics develops life sciences research tools for academic, government, biopharmaceutical, biotechnology and other institutions. Its integrated solutions combine instruments, consumables and software to analyze biological systems at single-cell and spatial resolution. The company’s main platforms include Chromium for high-throughput single-cell analysis, Visium for spatial analysis of tissues, and Xenium for in situ analysis of RNA targets in tissue. Its single-cell portfolio also includes QuantumScale RNA and methylation kits. Software such as Cell Ranger, Loupe Browser and Xenium Explorer supports experiment planning, data processing, visualization and exploration. 10x Genomics makes money by selling instruments, consumables and related products, primarily through its direct sales force in North America and certain regions of Europe, as well as through third-party distributors in other regions. It sells its products in over 50 countries. The company is headquartered in Pleasanton, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $TXG in the last 30 days.
See all $TXG insider activity →UBS kept 10x Genomics at Neutral and cut its price target to $61 from $90, a 32.2% reduction. This implies a 2.9% upside from the Nov 6 close of $59.28. Recent analyst targets for the company range from $60 to $100.
Citigroup kept 10x Genomics at Neutral but raised its price target to $60 from $50, a 20% increase. The new target suggests a 1.2% upside from the Nov 6 close of $59.28. Recent analyst price targets for 10x Genomics range from $68 to $110.
Stifel reaffirmed its Buy rating for 10x Genomics and increased its price target to $68 from $50, citing a 17.1% upside from the Nov 5 close of $58.06. Other recent analyst price targets for the company range from $70 to $110.
Over the past 7 days, AlphAI's AI scored 20 news stories mentioning TXG (10x Genomics, Inc.). Coverage has skewed bullish: 11 bullish, 6 neutral, and 3 bearish.
Recent TXG coverage spans financial news, earnings and technology.
Analyst downgrade suggests weaker outlook.
Analyst upgrade may provide modest upside pressure.
Analyst upgrade suggests upside potential.
Guidance raise suggests stronger demand and may lift the stock.
The new AI product could expand 10x's addressable market and drive incremental revenue.
AlphAI scores every news story that mentions TXG with an AI model for sentiment and relevance, and aggregates insider trades from 10x Genomics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
UBS kept 10x Genomics at Neutral and cut its price target to $61 from $90, a 32.2% reduction. This implies a 2.9% upside from the Nov 6 close of $59.28. Recent analyst targets for the company range from $60 to $100.
Citigroup kept 10x Genomics at Neutral but raised its price target to $60 from $50, a 20% increase. The new target suggests a 1.2% upside from the Nov 6 close of $59.28. Recent analyst price targets for 10x Genomics range from $68 to $110.
Stifel reaffirmed its Buy rating for 10x Genomics and increased its price target to $68 from $50, citing a 17.1% upside from the Nov 5 close of $58.06. Other recent analyst price targets for the company range from $70 to $110.
10x Genomics (TXG) reported Q3 2026 revenue of $150.7M, up 1% YoY. Launched Atera and Sentira, raising full-year revenue guidance to $625M-$635M. Gross margin improved to 75%, while operating loss narrowed to $16.1M.
10x Genomics launched Sentira Single Cell, a cloud app using AI agent Claude to automate single-cell data analysis. The tool allows researchers to query data in plain English, bypassing coding. According to the company, it speeds up analysis for non-programmers. 10x tested the agent on existing datasets but has not yet published accuracy figures.
10x Genomics (TXG) will report Q3 earnings on Thursday. Last quarter, it beat revenue and EPS estimates, reporting $151M in revenue, down 12.6% YoY. Analysts expect flat YoY revenue this quarter. Peers Illumina and West Pharmaceutical Services reported mixed results. TXG shares are down 32.8% over the last month, with an average price target of $77.50.
10x Genomics, Inc. (TXG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 28, 2026, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors o
10x Genomics launched Sentira Single Cell, a cloud-based AI app for analyzing Chromium data using Anthropic's Claude. The app is available now with promotional credits and consumption-based pricing, according to the company.
Analysts updated ratings and price targets for various U.S. companies. Notable changes include downgrades for 10x Genomics (TXG) and upgrades for Allegion (ALLE). Price targets were raised for AbbVie (ABBV), Amgen (AMGN), and others, while cuts were seen in sectors like retail and housing. Analysts favored growth and defensive sectors while showing caution toward consumer-sensitive areas.
Torex Gold Resources Inc. (TXG) appointed Lee Hodgkinson to its Board of Directors, effective November 1, 2026, maintaining an eight-member board after a recent departure. The move adds mining-focused financial expertise to the board.
